Crossmark

Real-world clinical evaluation of the Inflammatix TriVerity test for sepsis at the emergency department: an Acutelines study

Crossref DOI link: https://doi.org/10.1007/s11739-026-04457-0

Published Online: 2026-07-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

ter Voert, Michèle A. https://orcid.org/0009-0000-6606-8030
Lu, Jingyi https://orcid.org/0000-0002-0510-5034
Hincapié-Osorno, Carolina https://orcid.org/0000-0001-8582-1614
van der Aart, Tamar J. https://orcid.org/0000-0002-1518-8603
Ter Horst, Sanne https://orcid.org/0000-0001-9855-2919
Ünal, Mehtap https://orcid.org/0000-0002-0308-0291
Visser, Martje https://orcid.org/0009-0003-8043-2582
van Wijk, Raymond J. https://orcid.org/0000-0002-2106-7699
ter Maaten, Jan https://orcid.org/0000-0002-0353-4011
Whitfield, Natalie N. https://orcid.org/0000-0001-9937-9687
Khatri, Purvesh https://orcid.org/0000-0002-4143-4708
Sweeney, Timothy E. https://orcid.org/0000-0002-3596-1093
Blokzijl, Fredrike https://orcid.org/0000-0002-4120-761X
Li, Jie https://orcid.org/0000-0002-1006-9314
Bouma, Hjalmar R. https://orcid.org/0000-0003-1032-321X
License Information

Text and Data Mining valid from 2026-07-08

Version of Record valid from 2026-07-08
More Information

Article History

Received: 31 March 2026

Accepted: 25 June 2026

First Online: 8 July 2026

Declarations

:

: NW, PK, and TES are employees and stock option holders for Inflammatix.

: The study was approved by the local Medical Ethics Review Committee under protocol number 19378 and conducted according to the principles of the World Medical Association Declaration of Helsinki.